KRTX
Income statement / Annual
Last year (2023), Karuna Therapeutics, Inc.'s total revenue was $654,000.00,
a decrease of 93.85% from the previous year.
In 2023, Karuna Therapeutics, Inc.'s net income was -$433.68 M.
See Karuna Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$654,000.00
|
$10.64 M
|
$36.96 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.70 M |
$1.11 M |
$506,000.00 |
$145,000.00 |
$58,000.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$1.05 M |
$9.53 M |
$36.46 M |
-$145,000.00 |
-$58,000.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
-1.6 |
0.9 |
0.99 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$364.10 M
|
$224.25 M
|
$128.20 M
|
$43.41 M
|
$24.54 M
|
$11.54 M
|
$3.62 M
|
| General & Administrative
Expenses |
$131.33 M
|
$76.07 M
|
$52.62 M
|
$28.41 M
|
$20.87 M
|
$2.97 M
|
$1.19 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$131.33 M
|
$76.07 M
|
$52.62 M
|
$28.41 M
|
$20.87 M
|
$2.97 M
|
$1.19 M
|
| Other Expenses |
$588,000.00 |
$580,000.00 |
$254,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$495.43 M |
$300.31 M |
$180.82 M |
$71.82 M |
$45.41 M |
$14.51 M |
$4.81 M |
| Cost And Expenses |
$495.43 M |
$300.31 M |
$180.82 M |
$71.82 M |
$45.41 M |
$14.51 M |
$4.81 M |
| Interest Income |
$61.18 M |
$14.18 M |
$502,000.00 |
$3.31 M |
$2.53 M |
$25,000.00 |
$0.00 |
| Interest Expense |
$0.00 |
$14.18 M |
$0.00 |
$0.00 |
$945,000.00 |
$2.58 M |
$1.17 M |
| Depreciation &
Amortization |
$1.70 M
|
$1.11 M
|
$702,000.00
|
$3.31 M
|
$2.53 M
|
$6,000.00
|
$1,000.00
|
| EBITDA |
-$493.08 M
|
-$289.68 M
|
-$143.15 M
|
-$68.51 M
|
-$42.88 M
|
-$14.48 M
|
-$4.81 M
|
| EBITDA Ratio |
-753.94 |
-27.23 |
-3.87 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-756.54
|
-27.23
|
-3.89
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$61.77 M
|
$14.76 M
|
$54,000.00
|
$3.31 M
|
$1.45 M
|
-$3.00 M
|
-$1.23 M
|
| Income Before Tax |
-$433.01 M |
-$274.92 M |
-$143.80 M |
-$68.51 M |
-$43.96 M |
-$17.51 M |
-$6.03 M |
| Income Before Tax Ratio
|
-662.09
|
-25.85
|
-3.89
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$670,000.00 |
$1.42 M |
$6,000.00 |
$43,000.00 |
$887,000.00 |
-$419,000.00 |
$1.17 M |
| Net Income |
-$433.68 M |
-$276.34 M |
-$143.81 M |
-$68.55 M |
-$44.84 M |
-$17.51 M |
-$6.03 M |
| Net Income Ratio |
-663.12 |
-25.98 |
-3.89 |
0 |
0 |
0 |
0 |
| EPS |
-11.73 |
-8.74 |
-4.94 |
-2.59 |
-3.75 |
-1.61 |
-0.81 |
| EPS Diluted |
-11.73 |
-8.74 |
-4.94 |
-2.59 |
-3.75 |
-1.61 |
-0.81 |
| Weighted Average Shares
Out |
$36.96 M
|
$31.63 M
|
$29.14 M
|
$26.45 M
|
$11.96 M
|
$10.87 M
|
$7.42 M
|
| Weighted Average Shares
Out Diluted |
$36.96 M
|
$31.63 M
|
$29.14 M
|
$26.45 M
|
$11.96 M
|
$10.87 M
|
$7.42 M
|
| Link |
|
|
|
|
|
|
|
